Biomedtech Portfolio

Spikimm

SpikImm develops long-acting mAbs to prevent viral infections in imunocompromized patients, in particular transplant patients

SpikImm's Website

SpikImm, co-founded by Truffle Capital and Institut Pasteur in 2021, is a Biotech company developing monoclonal antibodies for the treatment of viral infections in vulnerable post-transplants patients.

LATEST NEWS

April 16, 2024

SpikImm Announces an Exclusive License with SATT Conectus for the Development of a Prophylactic mAb Against BK Virus

October 20, 2022

SpikImm announces the clinical trials start for SPK001, its monoclonal antibody against SARS-CoV-2

April 14, 2022

SpikImm's monoclonal antibody has demonstrated a potent and broad neutralization activity across all SARS-CoV-2 variants of concern

OTHER COMPANIES

PK Med

Locally administered therapeutic products to address inflammatory joint diseases and tissue regen...

Skinosive

Bio-adhesive UV filters for long lasting and broad-spectrum sun protection

Caranx Medical

Autonomous robot improving efficiency and safety in Transcatheter Aortic Valve Replacement (TAVI...

BariaTek

Minimally invasive, atraumatic, reversible and endoscopically delivered medical device to treat o...

Artedrone

Autonomous robotic solution to increase the accessibility of mechanical thrombectomy during acute...

Carbios

Biotechnology powering plastic and textile circularity

Affluent Medical

Minimally invasive, biomimetic and adjustable solutions for mitral regurgitation and urinary inco...

Abivax

Regulating the immune response through microRNA

Holistick Medical

Patent Foramen Ovale (PFO) treatment through next generation medical devices

Seacure

Seacure leverages natural processes to fight against coastal erosion and protect marine structures